Key result
Nebulised beta2-agonist therapy is not linked to serious arrhythmias within an hour despite falling potassium.
Why the study?
Does nebulised beta2-agonist therapy increase serious arrhythmias in patients with acute exacerbation of chronic airflow limitation?
Observational (n=20)
Does nebulised beta2-agonist therapy increase serious arrhythmias in patients with acute exacerbation of chronic airflow limitation?
Nebulised beta2-agonist therapy does not significantly increase serious arrhythmias in the short term despite inducing a fall in plasma potassium in patients with acute exacerbation of chronic airflow limitation.
Answers are grounded in this paper and cite their sources.
Supports short-term arrhythmia safety of nebulised beta2-agonists despite hypokalaemia; hypothesis-generating and requires confirmation in larger studies.
The effect on cardiac rhythm of the fall in plasma potassium concentration induced by nebulised beta2-agonist therapy was studied in 20 patients admitted to hospital with an acute exacerbation of their reversible chronic airflow limitation. Arrhythmias considered serious or potentially life-threatening were recorded in 13 patients (65%). However, there was no significant increase in these arrhythmias in the hour following administration of nebulised beta2-agonist despite a significant fall in plasma potassium concentration during this period.
No takes yet. Share an insight, caveat, or question.
Lim et al. (1989) conducted an observational in Acute exacerbation of reversible chronic airflow limitation (n=20). Nebulised beta2-agonist therapy was evaluated on Serious or potentially life-threatening arrhythmias. Nebulised beta2-agonist therapy did not significantly increase serious or potentially life-threatening arrhythmias in the hour following administration, despite a significant fall in plasma potassium.
Synapse has enriched 10 related papers. Consider them for comparative context: